P0784: Independent association between baseline simple endoscopic score for Crohn’s disease and C-reactive protein with Crohn’s disease-related complications: An analysis of the Randomized Evaluation of an Algorithm for Crohn’s Treatment – Study 2 (REACT2)ECCO'25Year: 2025
Authors: Jairath, V.(1)*;Joshi, N.(2);Clark, R.(2);Kristina, K.(3);Xuan, S.(2);Zou, G.(4);Peng, Y.(5);Dubcenco, E.(2);Feagan, B.(1);Dulai, P.S.(6);Sedano, R.(7,8,9);Ma, C.(10);
(1)Western University, Department of Medicine, London, Canada;(2)AbbVie Inc., Gastroenterology, North Chicago, United States;(3)AbbVie- Inc., Gastroenterology, North Chicago, United States;(4)Western University, Department of Epidemiology and Biostatistics and Robarts Research Institute, London, Canada;(5)AbbVie Inc, Gastroenterology, North Chicago, United States;(6)Northwestern University, Division of Gastroenterology and Hepatology, Chicago, United States;(7)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(8)Lawson Health Research Institute, Research, London, Canada;(9)Western University, Department of Epidemiology and Biostatistics, London, Canada;(10)University of Calgary, Departments of Medicine and Community Health Sciences, Calgary, Canada;
P0785: Protocol for a Priority Setting Partnership to identify the top 10 global research priorities for perianal Crohn’s diseaseECCO'25Year: 2025
Authors: Pelly, T.(1)*;
(1)St Marks Hospital, Fistula Research Unit, London, United Kingdom; Perianal Crohn's Disease Priority Setting Partnership Steering Group
1. Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of perianal Crohn’s disease: a systematic review and meta-analysis of population-based cohorts. Inflammatory Bowel Diseases. 2022 Oct 1;28(10):1477-84.
2. McCurdy JD, Chen JH, Golden S, Kukaswadia A, Sarah Power G, Ward R, Targownik LE. Perianal fistulas are associated with persistently higher direct health care costs in Crohn’s disease: a population-based study. Digestive Diseases and Sciences. 2023 Dec;68(12):4350-9.
3. Adegbola SO, Pisani A, Sahnan K, Tozer P, Ellul P, Warusavitarne J. Medical and surgical management of perianal Crohn’s disease. Annals of gastroenterology. 2018 Mar;31(2):129.
P0786: The short-term efficacy of Filgotinib on antibiotic-dependent/resistant pouchitis in patients with ulcerative colitis.ECCO'25Year: 2025
Authors: Uchino, M.(1)*;Ikeuchi, H.(1);Horio, Y.(1);Kuwahara, R.(1);Kusunoki, K.(1);Nagano, K.(1);Tomoo, Y.(1);Nomura, K.(1);
(1)Hyogo Medical University, Department of Gastroenterological Surgery- Division of Inflammatory Bowel Disease, Nishinomiya, Japan;
P0787: A large-scale comparison of clinical response to IBD therapies in white and non-white ethnicities.ECCO'25Year: 2025
Authors: Balarajah, S.(1,2)*;Martinez-Gili, L.(1);Alexander, J.L.(1,2,3);Mullish, B.H.(1,2);Perry, R.W.(1,4);Li, J.V.(1);Marchesi, J.R.(1);Parkes, M.(5,6);Orchard, T.R.(1,2);Hicks, L.C.(1,2);Williams, H.R.(1,2);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Department of Gastroenterology and Hepatology, London, United Kingdom;(3)St Mark’s Academic Institute, Gastroenterology, London, United Kingdom;(4)Chelsea and Westminster Hospital NHS Foundation Trust, Department of Gastroenterology- West Middlesex Hospital, London, United Kingdom;(5)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(6)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;
P0788: Exploring topics of Dutch Inflammatory Bowel Disease patient messages for improving transmural communication efficiency: A natural language processing approachECCO'25Year: 2025
Authors: Zhang, J.(1)*;Fijten, R.(1);Puts, S.(1);Hendrix, E.(2);Okegunna, Y.(1);Mujagic, Z.(2);Pierik, M.(2);
(1)Maastricht University Medical Centre+, Department of Radiation Oncology Maastro- GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands;(2)Maastricht University Medical Centre+, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;
1. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959-68. doi: 10.1016/S0140-6736(17)31327-2
2. Reimers N, Gurevych I. Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks. arXiv. Published online August 27, 2019. doi:10.48550/arXiv.1908.10084
3. de Vries W, van Cranenburgh A, Bisazza A, Caselli T, van Noord G, Nissim M. BERTje: A Dutch BERT Model. arXiv. Published online December 19, 2019. doi:10.48550/arXiv.1912.09582
P0789: Combined inhibition of TL1A and integrin β7 is superior to either monotherapy in mouse models of colitis and coadministration of SPY001 and SPY002 demonstrates no drug-drug effects on exposure in non-human primatesECCO'25Year: 2025
Authors: Siegel, M.(1);Friedman, J.(2)*;Nguyen, D.(2);McNally, J.(1);Kennedy, M.(1);Ballew, O.(1);Rose, M.(1);Spencer, A.(1);
(1)Spyre Therapeutics, Non-clinical Development, Waltham- MA, United States;(2)Spyre Therapeutics, Clinical Development, Waltham- MA, United States;
P0790: Effectiveness of Tofacitinib and Filgotinib as An Induction Therapy for Patients with Moderate-to-Severe Ulcerative Colitis: Real-World Comparison in Propensity Score-Matching AnalysisECCO'25Year: 2025
Authors: Yagi, S.(1)*;Fukui, H.(1);Ikenouchi, M.(1);Shiraishi, T.(1);Wakita, M.(1);Takagi, Y.(1);Sato, T.(1);Kawai, M.(1);Kamikozuru, K.(1);Yokoyama, Y.(1);Takagawa, T.(2);Tomita, T.(1);Shinzaki, S.(1);
(1)Hyogo Medical University, Department of Gastroenterology- Faculty of Medicine, Nishinomiya, Japan;(2)Hyogo Medical University, Center for Clinical Research and Education, Nishinomiya, Japan;
P0792: Remission rates in Complex Perianal Fistulizing Crohn's Disease – Real-life experience of a tertiary reference centerECCO'25Year: 2025
Authors: Silva, A.(1)*;Silva, E.(1);Brandão, P.(1);Sampaio, M.(1);Pedroto, I.(2);Santos, M.D.(1);Lago, P.(2);
(1)Centro Hospitalar Universitário de Santo António- Hospital de Santo António, Surgery, Porto, Portugal;(2)Centro Hospitalar Universitário de Santo António- Hospital de Santo António, Gastroenterology, Porto, Portugal;
1. Devi J, Ballard DH, Aswani-Omprakash T, Parian AM, Deepak P. Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies. Indian J Gastroenterol. 2024;43(1):48-63.
2. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–80.
3. Stevens TW, D’Haens GR, Duijvestein M, et al. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J. 2019;7:496-506.
4. Adegbola SO, Dibley L, Sahnan K, et al. Burden of disease and adaptation to life in patients with Crohn’s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020;18:1-13.
P0793: Correlation between patient centred disease control versus biochemical parameters in IBDECCO'25Year: 2025
Authors: Aliu, A.(1)*;Mujagic, Z.(2);Jeuring, S.(2);Pierik, M.(2);
(1)Maastricht University NUTRIM, Gastroenterology, Maastricht, The Netherlands;(2)Maastricht University Medical Center, Gastroenterology, Maastricht, The Netherlands;
P0794: Incidence of Clostridium Difficile Infection and enteric pathogens as a cause of Pediatric Inflammatory Bowel Disease flare up, retrospective study in the United Arab Emirates.ECCO'25Year: 2025
Authors: Alsarhan, A.(1)*;Alshaibah, K.(2);tzivinikos, C.(3);Jasem, R.(4);
(1)Aljalila childrens hospital, Peds Gastroenterology, Dubai, United Arab Emirates;(2)Al Jalila Children's hospital, Pediatric medicine, Dubai, United Arab Emirates;(3)Al Jalila Children's hospital, Pediatric Gastroenterology, Dubai, United Arab Emirates;(4)University of Sharjah, Medical affairs, Sharjah, United Arab Emirates;
Kolho KL, Klemola P, Simonen-Tikka ML, Ollonen ML, Roivainen M. Enteric viral pathogens in children with inflammatory bowel disease. J Med Virol. 2012 Feb;84(2):345-7. doi: 10.1002/jmv.23193. PMID: 22170557.
Axelrad JE, Joelson A, Green PHR, Lawlor G, Lichtiger S, Cadwell K, Lebwohl B. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530-1539. doi: 10.1038/s41395-018-0211-8. Epub 2018 Aug 3. PMID: 30072777; PMCID: PMC7939066.
Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015 Jan 27;313(4):398-408. doi: 10.1001/jama.2014.17103. PMID: 25626036; PMCID: PMC6561347.
Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol. 2021 May 30;14:17562848211020285. doi: 10.1177/17562848211020285. PMID: 34104215; PMCID: PMC8170344.
P0795: Clinical symptoms, C-reactive protein and albumin at admission to hospital poorly correlate with refractoriness to intravenous steroids in Acute Severe Ulcerative Colitis – posthoc analysis of the IASO trialECCO'25Year: 2025
Authors: Drobne, D.(1,2,3)*;Vaja, S.(4);Qian, W.(4);Pavey, H.(4);Subramanian, S.(1);Brezina, B.(1);Steel, A.(5);Speight, A.(6);Lamb, C.(6);Sebastian, S.(7);Din, S.(8);Arnott, I.(8);Galea, J.(9);Hendy, P.(10);Selinger, C.(11);Steed, H.(12);Jairath, V.(13);Parkes , M.(1);Kaser, A.(14);Raine, T.(1);
(1)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(2)University of Ljubljana, Medical Faculty, Ljubljana, Slovenia;(3)Unversity Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(4)Cambridge University Hospitals NHS Foundation Trust, CCTU Cambridge Clinical Trials Unit, Cambridge, United Kingdom;(5)Royal Liverpool University Hospital, Royal Liverpool University Hospital, Liverpool, United Kingdom;(6)Royal Victoria Infirmary, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom;(7)Hull University Teaching Hospitals, IBD Unit, Hull, United Kingdom;(8)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(9)Cardiff University, Cardiff University, Cardiff, United Kingdom;(10)Chelsea and Westminster NHS Trust London, Department of Gastroenterology, London, United Kingdom;(11)St James University Hospital, St James University Hospital, Leeds, United Kingdom;(12)University of Wolverhampton, University of Wolverhampton, Wolverhampton, United Kingdom;(13)Western University- Canada, Department of Gastroenterology, Western University- Canada, Canada;(14)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;
1. Thomas, M. G. et al. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 9, e023765 (2019).
2. Raine, T. et al. OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO). J. Crohns Colitis 17, i43–i46 (2023).
P0796: Comparison of Disease Severity, Treatment, and Outcomes in Elderly and Younger Patients Hospitalized with Acute Severe Ulcerative Colitis (ASUC)ECCO'25Year: 2025
Authors: Ollech, J.(1)*;Lev Kolnik, R.(2);Yanai, H.(2);Dotan , I.(2);
(1)Rabin Medical Center, Gastroenterology, Petach Tikva, Israel;(2)Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;
P0797: Clinical outcomes of dose escalated vedolizumab in Inflammatory Bowel Disease: a retrospective tertiary centre experienceECCO'25Year: 2025
Authors: Gondal, F.(1)*;Salehi, O.(1);Terlato, M.(1);Pillay, L.(1);Macrae, F.(1);Rentsch, C.(1);Dimovski, S.(1);Segal, J.P.(1);
(1)The Royal Melbourne Hospital, Department of Gastroenterology, Parkville, Australia;
1. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 2021;19(4):854-855.
2. Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therapeutic Advances in Gastroenterology. 2018;11:175628481877278.
3. Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2017;46(1):3-15. doi:https://doi.org/10.1111/apt.14075
P0799: Efficacy and Safety of Dual Therapy for Refractory Inflammatory Bowel Disease in a Danish CohortECCO'25Year: 2025
Authors: Haase, A.M.(1);Bendix, M.(2)*;
(1)Aarhus University Hospital, Hepatology and gastroenterology department, Aarhus, Denmark;(2)Regional Hospital Randers, Medical department, Randers, Denmark;
1. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of
ESPGHAN.Inflamm Bowel Dis, 2024. 30(2): p. 159-166.
2. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2022. 20(3):
p. e361-e379.
P0800: Efficacy of filgotinib in patients with ulcerative colitis refractory to prior biologics.ECCO'25Year: 2025
Authors: Suarez, A.(1)*;Ruz Zafra, P.(1);Leo Carnerero, E.(1);Rojas Feria, M.(1);De la Cruz Ramírez, M.D.(1);Rodríguez Pérez, A.Á.(2);Villalba Moreno, Á.M.(2);Trigo Salado, C.(1);
(1)Virgen del Rocío University Hospital, Gastroenterology Department, Seville, Spain;(2)Virgen del Rocío University Hospital, Pharmacy Department, Seville, Spain;
P0802: Effect of proctocolectomy with diverting ileostomy on Renal FunctionECCO'25Year: 2025
Authors: Futatsuki, R.(1)*;Tani, K.(1);Kouroku, M.(2);Ito, A.(2);Yonezawa, M.(2);Ogawa, S.(1);Yamaguchi, S.(1);
(1)Tokyo Women's Medical University, Department of Surgery- Institute of Gastroenterology, Tokyo, Japan;(2)Tokyo Women's Medical University, Department of Internal Medicine- Institute of Gastroenterology, Tokyo, Japan;
P0803: Biosimilar Therapy in IBD: Real-World Evidence from Saudi ArabiaECCO'25Year: 2025
Authors: Mosli, M.H.A.(1)*;Bakkari, S.(2);Al Jahdali, A.(3);Batwa, F.(4);Hassanein, A.(5);
(1)King Abdulaziz University- Faculty of Medicine, Medicine, Jeddah, Saudi Arabia;(2)king saud medical city, Internal Medicine, Riyadh, Saudi Arabia;(3)National Guard Hospital in Riyadh, Internal Medicine, Riyadh, Saudi Arabia;(4)National Guard Hospital in Jeddah, Internal Medicine, jeddah, Saudi Arabia;(5)Hikma, Medical Affairs, Riyadh, Saudi Arabia;
Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases. 2022 May 16;10(14):4327-4333. doi: 10.12998/wjcc.v10.i14.4327. PMID: 35663066; PMCID: PMC9125297.
